← Every company
BioCryst Pharmaceuticals Inc Patents
What BioCryst Pharmaceuticals Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
BCRX on carbonthat →Filings on file
34
Granted
6
Still pending
28
Filed under
4 names
34 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| PLASMA KALLIKREIN INHIBITORS AND METHODS OF USE THEREOF IN OCULAR DISORDERSA61K 9/0048, A61K 31/4418, A61P 27/02, A61K 9/0019, A61K 9/0021, A61K 31/4412, A61K 47/30, A61K 47/32, C07K 16/40Filed as BIOCRYST PHARMACEUTICALS, INC.2026-03-04Yarlagadda BABU | pending |
| INHIBITORS OF COMPLEMENT PROTEIN C5Filed as BIOCRYST PHARMACEUTICALS, INC.2026-02-13PRAVIN L. KOTIAN | pending |
| TRICYCLIC INHIBITORS OF COMPLEMENT PROTEIN C5Filed as BIOCRYST PHARMACEUTICALS, INC.2026-02-13PRAVIN L. KOTIAN | pending |
| METHOD OF PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA IN PEDIATRIC PATIENTS AND COMPOSITIONS FOR USE IN SUCH METHODSFiled as BIOCRYST PHARMACEUTICALS, INC.2026-02-10TATIANA KHARITON | pending |
| USE OF AVORALSTAT IN THE TREATMENT OF DIABETIC MACULAR EDEMA AND RELATED OCULAR DISEASESFiled as BIOCRYST PHARMACEUTICALS, INC.2026-01-09JOHN MICHAEL SAUER | pending |
| ORAL COMPLEMENT FACTOR D INHIBITORSA61K 31/343, C07C 217/48, C07D 307/80, A61P 27/02, A61P 7/00, A61P 25/28, A61P 9/00, A61P 13/12, A61P 25/00, A61K 31/381, A61K 31/404, A61K 31/4155, A61K 31/416, A61K 31/423, A61K 31/437, A61K 31/443, A61K 31/496, A61K 31/506, A61K 31/5377, C07D 209/12, C07D 209/42, C07D 231/56, C07D 261/20, C07D 273/04, C07D 275/04, C07D 307/81, C07D 333/56, C07D 333/58, C07D 401/04, C07D 405/04, C07D 405/06, C07D 405/10, C07D 405/12, C07D 407/12, C07D 407/14, C07D 417/12, C07D 471/04, C07D 491/048, C07D 493/04, C07D 495/04Filed as BioCryst Pharmaceuticals, Inc.2025-12-30Pravin L. Kotian | pending |
| Method of Prophylaxis to Prevent Attacks of Hereditary Angioedema in Pediatric Patients and Compositions for Use in Such MethodsFiled as BIOCRYST PHARMACEUTICALS, INC2025-12-12Tatiana Khariton | pending |
| SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORSC07D 239/70, C07D 307/81, C07D 401/10, A61P 27/02, A61P 37/00, A61P 25/28, A61P 9/00, A61P 13/12, A61P 25/00, A61K 9/50, A61K 31/343, A61K 31/4178, A61K 31/53, A61K 31/5377, C07D 209/08, C07D 209/12, C07D 231/56, C07D 235/08, C07D 261/20, C07D 263/54, C07D 307/79, C07D 307/80, C07D 307/83, C07D 333/54, C07D 333/56, C07D 333/64, C07D 401/04, C07D 401/12, C07D 403/10, C07D 405/04, C07D 405/10, C07D 405/12, C07D 407/04, C07D 407/10, C07D 409/12, C07D 413/04, C07D 471/04, C07D 487/04, C07D 491/048, C07D 495/04Filed as BioCryst Pharmaceuticals, Inc.2025-12-08Pravin L. Kotian | pending |
| PROCESS-SCALE SYNTHESIS OF A PLASMA KALLIKREIN INHIBITORC07C 253/30, C07D 231/14, C07C2602/02, A61K 31/415, C07C 255/58Filed as BioCryst Pharmaceuticals, Inc.2025-11-24Yahya El-Kattan | pending |
| BIFUNCTIONAL THERAPEUTIC ANTIBODY TARGETING THE COMPLEMENT CASCADEFiled as BIOCRYST PHARMACEUTICALS, INC.2025-10-31YARLAGADDA S. BABU | pending |
| USE OF AVORALSTAT IN THE TREATMENT OF DIABETIC MACULAR EDEMA AND RELATED OCULAR DISEASESFiled as BIOCRYST PHARMACEUTICALS, INC2025-09-09John Michael Sauer | pending |
| CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORC07D 231/14, C07D 231/44, A23L 33/10, A61P 7/10, A61P 27/02, A61P 7/00, A61P 7/02, A61P 7/04, A61P 9/10, A61P 19/02, A61P 3/10, A61P 29/00, A23V2002/00, A61K 9/0019, A61K 9/0029, A61K 9/0053, A61K 31/415, C07B2200/13Filed as BioCryst Pharmaceuticals, Inc.2025-08-28Yahya El-Kattan | 12590069 |
| CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORC07D 231/14, C07D 231/44, A23L 33/10, A61P 7/10, A61P 27/02, A61P 7/00, A61P 7/02, A61P 7/04, A61P 9/10, A61P 19/02, A61P 3/10, A61P 29/00, A23V2002/00, A61K 9/0019, A61K 9/0029, A61K 9/0053, A61K 31/415, C07B2200/13Filed as BioCryst Pharmaceuticals, Inc.2025-08-28Yahya El-Kattan | 12545646 |
| CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORC07D 231/14, C07D 231/44, A23L 33/10, A61P 7/10, A61P 27/02, A61P 7/00, A61P 7/02, A61P 7/04, A61P 9/10, A61P 19/02, A61P 3/10, A61P 29/00, A23V2002/00, A61K 9/0019, A61K 9/0029, A61K 9/0053, A61K 31/415, C07B2200/13Filed as BioCryst Pharmaceuticals, Inc.2025-08-28Yahya El-Kattan | 12590068 |
| CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORC07D 231/14, C07D 231/44, A23L 33/10, A61P 7/10, A61P 27/02, A61P 7/00, A61P 7/02, A61P 7/04, A61P 9/10, A61P 19/02, A61P 3/10, A61P 29/00, A23V2002/00, A61K 9/0019, A61K 9/0029, A61K 9/0053, A61K 31/415, C07B2200/13Filed as BioCryst Pharmaceuticals, Inc.2025-08-28Yahya El-Kattan | 12552750 |
| CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORC07D 231/14, C07D 231/44, A23L 33/10, A61P 7/10, A61P 27/02, A61P 7/00, A61P 7/02, A61P 7/04, A61P 9/10, A61P 19/02, A61P 3/10, A61P 29/00, A23V2002/00, A61K 9/0019, A61K 9/0029, A61K 9/0053, A61K 31/415, C07B2200/13Filed as BioCryst Pharmaceuticals, Inc.2025-08-28Yahya El-Kattan | 12545647 |
| CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORC07D 231/14, C07D 231/44, A23L 33/10, A61P 7/10, A61P 27/02, A61P 7/00, A61P 7/02, A61P 7/04, A61P 9/10, A61P 19/02, A61P 3/10, A61P 29/00, A23V2002/00, A61K 9/0019, A61K 9/0029, A61K 9/0053, A61K 31/415, C07B2200/13Filed as BioCryst Pharmaceuticals, Inc.2025-08-28Yahya El-Kattan | 12545645 |
| Method of Prophylaxis to Prevent Attacks of Hereditary Angioedema in Pediatric Patients and Compositions for Use in Such MethodsFiled as BIOCRYST PHARMACEUTICALS, INC2025-07-25Tatiana Khariton | pending |
| ORAL DOSAGE FORMS AND ORAL DOSING REGIMENS FOR TREATMENT OF COMPLEMENT MEDIATED DISEASESFiled as BioCryst Pharmaceuticals, Inc.2025-07-02Yarlagadda S. Babu | pending |
| INHIBITORS OF COMPLEMENT PROTEIN C5Filed as BioCryst Pharmaceuticals, Inc.2025-06-27Pravin L. Kotian | pending |
| CRYSTALLINE SALTS OF A PLASMA KALLIKREIN INHIBITORC07D 231/14, C07D 231/44, A23L 33/10, A61P 7/10, A61P 27/02, A61P 7/00, A61P 7/02, A61P 7/04, A61P 9/10, A61P 19/02, A61P 3/10, A61P 29/00, A23V2002/00, A61K 9/0019, A61K 9/0029, A61K 9/0053, A61K 31/415, C07B2200/13Filed as BioCryst Pharmaceuticals, Inc.2025-05-30Yahya El-Kattan | pending |
| TRICYCLIC INHIBITORS OF COMPLEMENT PROTEIN C5Filed as BioCryst Pharmaceuticals, Inc.2025-02-14Pravin L. Kotian | pending |
| INHIBITORS OF COMPLEMENT PROTEIN C5Filed as BioCryst Pharmaceuticals, Inc.2025-02-14Pravin L. Kotian | pending |
| METHOD OF PROPHYLAXIS TO PREVENT ATTACKS OF HEREDITARY ANGIOEDEMA IN PEDIATRIC PATIENTS AND COMPOSITIONS FOR USE IN SUCH METHODSFiled as BIOCRYST PHARMACEUTICALS, INC2025-02-10Tatiana Khariton | pending |
| FUSION PROTEIN INHIBITORS OF KLK5C07K 14/811, A61P 37/00, A61P 17/00, A61P 35/00, A61K 38/00, C07K2319/30, C07K2319/50Filed as BioCryst Pharmaceuticals, Inc.2025-01-17Yarlagadda S. Babu | pending |
| USE OF AVORALSTAT IN THE TREATMENT OF DIABETIC MACULAR EDEMA AND RELATED OCULAR DISEASESFiled as BIOCRYST PHARMACEUTICALS, INC2025-01-12John Michael Sauer | pending |
| BIFUNCTIONAL THERAPEUTIC ANTIBODY TARGETING THE COMPLEMENT CASCADEFiled as BioCryst Pharmaceuticals, Inc.2024-11-01Yarlagadda S. Babu | pending |
| ANTI-C2 BINDING AGENTS AND CONJUGATES THEREOFFiled as BIOCRYST PHARMACEUTICALS, INC.2024-11-01YARLAGADDA S. BABU | pending |
| HUMAN PLASMA KALLIKREIN INHIBITORSC07D 231/14, A61P 7/10, A61P 27/02, A61P 1/02, A61P 7/00, A61P 7/02, A61P 7/04, A61P 9/10, A61P 43/00, A61P 9/00, A61P 11/04, A61P 19/02, A61P 3/10, A61P 9/12, A61P 13/02, A61P 13/12, A61P 31/04, A61P 25/00, A61P 29/00, A61P 1/04, A61K 31/415, A61K 31/4155, C07D 401/04, C07D 401/12, C07D 401/14, C07D 403/04, C07D 403/12, C07D 403/14, C07D 405/12, C07D 413/04, C07D 413/12, C07D 417/12Filed as BioCryst Pharmaceuticals, Inc.2024-10-11Pravin L. Kotian | pending |
| HUMAN PLASMA KALLIKREIN INHIBITORSC07D 231/14, A61P 7/10, A61P 27/02, A61P 1/02, A61P 7/00, A61P 7/02, A61P 7/04, A61P 9/10, A61P 43/00, A61P 9/00, A61P 11/04, A61P 19/02, A61P 3/10, A61P 9/12, A61P 13/02, A61P 13/12, A61P 31/04, A61P 25/00, A61P 29/00, A61P 1/04, A61K 31/415, A61K 31/4155, C07D 401/04, C07D 401/12, C07D 401/14, C07D 403/04, C07D 403/12, C07D 403/14, C07D 405/12, C07D 413/04, C07D 413/12, C07D 417/12Filed as BioCryst Pharmaceuticals, Inc.2024-09-24Pravin L. Kotian | pending |
| TRICYCLIC HETEROAROMATIC INHIBITORS OF KLK5Filed as BIOCRYST PHARMACEUTICALS, INC.2024-08-23PRAVIN L. KOTIAN | pending |
| IMIDAZOLE-CONTAINING INHIBITORS OF ALK2 KINASEA61P 19/00, C07D 487/04, C07D 491/048, A61P 35/00, A61K 31/407, A61K 31/519, A61K 31/53, A61K 31/5377, C07B2200/07, C07D 233/88, C07D 401/12, C07D 401/14, C07D 403/12, C07D 403/14, C07D 405/12, C07D 405/14, C07D 471/04, C07D 473/16, C07D 473/34, C07D 495/04, C07D 513/04, C07D 519/00Filed as BioCryst Pharmaceuticals, Inc.2024-04-26Pravin L. Kotian | pending |
| SUBSTITUTED BENZOFURAN, BENZOPYRROLE, BENZOTHIOPHENE, AND STRUCTURALLY RELATED COMPLEMENT INHIBITORSC07D 239/70, C07D 307/81, C07D 401/10, A61P 27/02, A61P 37/00, A61P 25/28, A61P 9/00, A61P 13/12, A61P 25/00, A61K 9/50, A61K 31/343, A61K 31/4178, A61K 31/53, A61K 31/5377, C07D 209/08, C07D 209/12, C07D 231/56, C07D 235/08, C07D 261/20, C07D 263/54, C07D 307/79, C07D 307/80, C07D 307/83, C07D 333/54, C07D 333/56, C07D 333/64, C07D 401/04, C07D 401/12, C07D 403/10, C07D 405/04, C07D 405/10, C07D 405/12, C07D 407/04, C07D 407/10, C07D 409/12, C07D 413/04, C07D 471/04, C07D 487/04, C07D 491/048, C07D 495/04Filed as BioCryst Pharmaceuticals, Inc2024-01-08Pravin L. Kotian | pending |
| ORAL DOSAGE FORMS AND ORAL DOSING REGIMENS FOR TREATMENT OF COMPLEMENT MEDIATED DISEASESFiled as BIOCRYST PHARMACEUTICALS, INC.2024-01-05YARLAGADDA S. BABU | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on BCRX
Company overviewEverything on BCRX in one place, with the price.SEC filingsWhat BCRX's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat BCRX's own officers and directors buy and sell.Executive payWhat BCRX awarded its chief executive, and what it became.Who owns itEvery manager reporting a position in BCRX.Funds holding itWhich funds and ETFs hold BCRX, and how big a bet.Federal contractsWhat federal agencies pay BCRX.